Capital Markets Event
Updated : 07:02
10 April 2019
Cello Health plc
("Cello" or the "Group")
Capital Markets Event
Cello Health plc (AIM: CLL), the healthcare-led advisory group, is this afternoon hosting a capital markets event in London for analysts and institutional investors. The event will focus on the Group's Cello Health division and its strategic growth opportunities in the pharmaceutical and biotechnology industries worldwide.
The event will begin at 2.30pm at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further details please contact Buchanan on 020 7466 5000 or email cello@buchanan.uk.com.
A copy of the presentations accompanying the event will be made available later today at the Group's website: https://cellohealthplc.com.
No new material information will be disclosed during the event.
Enquiries:
Cello Health plc | 020 7812 8460 |
Mark Scott, Chief Executive | |
Mark Bentley, Group Finance Director | |
Cenkos Securities (Nominated adviser and broker) | 020 7397 8900 |
Mark Connelly | |
Harry Hargreaves | |
Buchanan | 020 7466 5000 |
Mark Court | |
Jamie Hooper | |
Sophie Wills |
About Cello Health plc
Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit: https://cellohealthplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.